Home/Pipeline/NA-704

NA-704

Amyotrophic Lateral Sclerosis (ALS)

Phase 2BActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 2B

Status

Active

Company

Biomed

About Biomed

Biomed Industries is a late-stage private biotech with a broad and advanced pipeline targeting major neurodegenerative, metabolic, and cardiovascular diseases. Its core strategy is underpinned by a proprietary 'Unified Acceleration Platform,' a theoretical and AI-driven framework positing shared biological dysfunctions across these disease areas. The company has multiple Phase 2 and Phase 3 assets, most notably NA-931 for obesity and NA-831 for Alzheimer's, and one FDA-approved device, the MICROS Infusion System.

View full company profile

Therapeutic Areas

Neurological Diseases Metabolic Disorders Cardiovascular Diseases Rare Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active